Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Non-Current Assets came in at $428.5 million in Q1 2026, down 2.23% YoY from $438.3 million in Q1 2025, and little changed on a QoQ basis from $429.8 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Non-Current Assets data on file, last reported at $428.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 2.23% year-over-year to $428.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 1.86% YoY) and the FY2025 annual result came in at $434.7 million, down 2.18% from the prior year.
- Non-Current Assets steadied at $428.5 million in Q1 2026, from $429.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $444.3 million in Q3 2024 to a low of $285.9 million in Q1 2022.
- A 5-year average of $381.6 million and a median of $413.5 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 68.17% in 2022, down 11.95% in 2022.
- Tracing ARWR's Non-Current Assets over 5 years: stood at $316.5 million in 2022, then gained by 22.72% to $388.4 million in 2023, then climbed by 14.1% to $443.2 million in 2024, then dropped by 3.02% to $429.8 million in 2025, then declined by 0.3% to $428.5 million in 2026.
- The last three Non-Current Assets figures came in at $428.5 million (Q1 2026), $429.8 million (Q4 2025), and $434.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 440.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 440.60 Mn |
| Mar 31, 2026 | 428.51 Mn |
| Dec 31, 2025 | 429.79 Mn |
| Sep 30, 2025 | 434.66 Mn |
| Jun 30, 2025 | 433.69 Mn |
| Mar 31, 2025 | 438.28 Mn |
| Dec 31, 2024 | 443.16 Mn |
| Sep 30, 2024 | 444.33 Mn |
| Jun 30, 2024 | 433.70 Mn |
| Mar 31, 2024 | 413.50 Mn |
| Dec 31, 2023 | 388.39 Mn |
| Sep 30, 2023 | 349.08 Mn |
| Jun 30, 2023 | 325.69 Mn |
| Mar 31, 2023 | 316.50 Mn |
| Dec 31, 2022 | 316.49 Mn |
| Sep 30, 2022 | 286.64 Mn |
| Jun 30, 2022 | 319.39 Mn |
| Mar 31, 2022 | 285.95 Mn |
| Dec 31, 2021 | 300.26 Mn |
| Sep 30, 2021 | 325.55 Mn |